Pre-operative mFOLFIRINOX or PAXG regimen for stage I-III #PDAC #ASCO25 🔎Phs-III 👉mEFS 16.2 vs 10 mo 👉mOS 37 vs 26 mo 🧐 OS benefit, but intensive treatment ESMO - Eur. Oncology

What will my life look like after surgery? STAYHOME helps answer for older adults for cancer surgery: 🏡individualized risk of staying home at 6 & 12 months 😷uses preop info ✅discrimination & calibration JAMA Surgery jamanetwork.com/journals/jamas…

FOLFIRINOX or Gemcitabine in Locally Advanced PDAC Journal of Clinical Oncology doi.org/10.1200/JCO-24… 🔎NEOPAN phs-3 👉ORR 15 vs 42.4% 👉mPFS 9.7 vs 7.7 mo 👉mOS 15.7 vs 15.4 mo 🧐Pos. study, but no OS benefit ESMO - Eur. Oncology

Thanks Alexander Sherry Ethan Ludmir MD and Pavlos Msaouel for this wonderful collaboration at the crossroads of statistics and oncology!

🎧 New ESMO - Eur. Oncology upper GI podcast! We unpack key #ASCO25 updates in #PancreaticCancer & #BiliaryCancer: ✔️ CASSANDRA ✔️ PANOVA-3 ✔️ Elraglusib ✔️ GAIN & POLCA-GB w/ Arndt Vogel & Florian Castet 🎙 Listen: open.spotify.com/episode/47uQnC… #GIonc

Excited to share our latest work in SURGERY Journal previously presented at Assoc4AcademicSurgery where we stratified patients relative to risk for 90-day mortality and long-tern survival following resection for ICC. Timothy M. Pawlik Ohio State Wexner Medical Center Surgery Dept. Cleveland Clinic Florida sciencedirect.com/science/articl…

🎙️ New #ESMO Podcast – Controversies in Upper GI Cancers 📌 Radiotherapy in borderline resectable #PDAC: Evidence vs practice – when does it make sense? Dr. Nina Niu Sanford & Bas Groot Koerkamp join me to discuss a case & key trials. 🎧 Listen: open.spotify.com/episode/6NFOKd… #PancreaticCancer

🕯️ In Memory of Professor Hans Jeekel We are deeply saddened by the passing of Professor Hans Jeekel, a true pioneer in hernia surgery and a visionary in our field. It was an honour to award him with a Lifetime Achievement Award at the EHS Congress in Paris last June—one final

PREOPANC2 is a great ex of ignoring data that doesn't fit one's priors. Many (myself included) were surprised by results, but it's a Ph3 RCT & data are the data. Gem-based RT is cheaper, less toxic than FFX; future trials should consider building off this regimen as baseline.

mFOLFIRINOX or S-IROX vs Nab-Paclitaxel + Gemcitabine in Metastatic or Recurrent Pancreatic Cancer (GENERATE, JCOG1611) 💥mFOLFIRINOX or S-IROX was not found to be superior to gem+ nab-pac; in fact, gem+nab-paclitaxel showed numerically better outcomes ascopubs.org/doi/10.1200/JC…

According to a study co-led by researchers at MSK and published in Nature Medicine, a new vaccine shows encouraging early results as a potential ready-made treatment for patients with pancreatic or colorectal cancer. Unlike individualized cancer vaccines, which are tailored to

Congratulations and thanks for the opportunity to contribute on Biliary Tumors Cholangiocarcinoma Foundation

Pleased to share that Shackelford’s Surgery of the Alimentary Tract, 9th Edition has been published. I had the privilege of contributing to the section on GIST under the mentorship of Dr. Jason Sicklick, from whom I’ve learned, and continue to learn.

.Michael Lidsky, MD, FACS of Duke Surgical Oncology and Duke Cancer is leading EA2222/PUMP, a randomized phase 3 study for patients with #Colorectal liver metastases. Learn more: bit.ly/ea2222-pump cc : Colorectal Cancer Alliance, Fight Colorectal Cancer, ACS National Colorectal Cancer Roundtable

⛽️New data incoming for hepatic artery infusion pump Where are we coming from? What is in the works? 🎧Review this & more with PIs of ongoing trials Bas Groot Koerkamp & Michael Lidsky, MD, FACS as they join Noah Cohen and I in new #SurgOncToday podcast🎙️ podcasts.apple.com/ca/podcast/sur…

Had a great time recording this podcast w/ Bas Groot Koerkamp Julie Hallet and Noah Cohen, in which we discuss #HAI and how we are working to address the age-old knowledge gaps that remain after decades of therapy. Society of Surgical Oncology AHPBA ECOG-ACRIN Cancer Research Group Duke Surgical Oncology Michael D’Angelica Shishir K. Maithel

Really looking forward to this! Memorial Sloan Kettering Cancer Center Duke Surgical Oncology Michael D’Angelica Lily Saadat Vinod BalachandranMD Eileen M O’Reilly Ghassan Abou-Alfa Peter Kingham

PREOPANC-2 published today in Lancet Oncology: authors.elsevier.com/a/1llTf5EIIgTS… together with DPCG and Marc Besselink

🆕Online today: Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable #pancreaticpancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trial Bas Groot Koerkamp, Marc Besselink, Dutch Pancreatic Cancer Group thelancet.com/journals/lanon…